5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Alembic Pharmaceuticals Ltd.

•
alembicpharmaceuticals.comBSE: 533573NSE: APLLTD
Market Cap₹ 16,075 Cr.
Current Price
High / Low₹ 998 / 636
Stock P/E21.9
Book Value₹ 296
Price to Book2.32
Dividend Yield1.47 %
ROCE11.3 %
ROE11.8 %
Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Latest quarter profit grew 90.3% YoY, showing strong momentum
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.00x)
  • Company has been maintaining a healthy dividend payout of 36.8%
  • Company has a consistent dividend-paying track record
  • Stock looks reasonably valued - P/E of 21.9 is below its historical median
  • Company comfortably covers its interest (8.6x coverage)

CONS

  • Company has delivered a poor profit growth of -10.2% over past five years
  • Company has delivered a poor sales growth of 5.6% over past five years
  • Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.APLLTD817.8023.1816074.931.47172.3612.192149.7725.6611.7415.46
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,3321,4791,5881,4751,4761,5801,4061,5711,4941,7961,6421,7191,868
1,1671,2711,2511,1861,1841,3211,2261,4001,2801,4931,3711,4451,626
Operating Profit166207337288291259180171214303272274242
OPM %12.44%14.03%21.23%19.54%19.75%16.42%12.79%10.87%14.30%16.89%16.54%15.95%12.95%
129373291513811-32114
Interest14151510131822242323221921
Depreciation66676969697070697376808283
Profit before Tax9813425721621320010492126216139173256
Tax %0.00%0.00%9.14%6.61%17.36%17.12%17.34%17.72%17.53%17.10%17.52%-40.13%23.04%
Net Profit981342332021761668675104179114243197
4.966.8111.8710.278.968.434.373.835.279.125.8212.3710.02

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
2,9862,9453,6604,1335,0675,0355,1495,8746,0336,6517,025
2,3532,3472,8012,9413,6184,1274,4854,8765,1375,5895,934
Operating Profit6335998591,1921,4499096649988961,0621,091
OPM %21.18%20.32%23.48%28.84%28.60%18.05%12.90%16.99%14.85%15.97%15.53%
34126136845143266-11-5
Interest32152513174954768785
Depreciation83102106136183285273271277311320
Profit before Tax5505357651,1671,338658346704609654784
Tax %21.66%21.16%20.06%16.92%18.03%17.39%-0.23%5.36%17.33%2.09%6.46%
Net Profit4314226119691,097544347666503640734
EPS22.8422.3832.4251.4256.6027.6517.6433.9125.6032.58—
Dividend Payout %17.51%17.87%16.96%19.45%25.09%36.16%45.35%32.44%42.97%36.83%—

COMPOUNDED SALES GROWTH

10 Years:
8%
5 Years:
6%
3 Years:
9%

COMPOUNDED PROFIT GROWTH

10 Years:
-1%
5 Years:
-10%
3 Years:
23%

STOCK PRICE CAGR

10 Years:
3%
5 Years:
1%
3 Years:
2%
1 Year:
-14%

RETURN ON EQUITY

10 Years:
18%
5 Years:
11%
3 Years:
12%
Last Year:
12%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Jul 29

₹ 6

Rs.12.0000 per share(600%)Final Dividend

2025

Jul 29

₹ 5.50

Rs.11.0000 per share(550%)Final Dividend

2024

Jul 15

₹ 5.50

Rs.11.0000 per share(550%)Final Dividend

2023

Jul 28

₹ 4

Rs.8.0000 per share(400%)Final Dividend

2022

Aug 17

Interim Dividend

2021

Jul 19

₹ 7

Rs.14.0000 per share(700%)Dividend

2019

Jul 18

₹ 2.75

Rs.5.5000 per share(275%)Dividend

2018

Jul 18

₹ 2

Rs.4.0000 per share(200%)Dividend

2017

Jul 11

₹ 2

Rs.4.0000 per share(200%)Dividend

2016

Jul 20

₹ 2

Rs.4.0000 per share(200%)Dividend

2022

May 2

₹ 5

Rs.10.0000 per share(500%)Dividend

2026

Jul 10

₹ 6

Rs.12.0000 per share(600%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital38383838393939393939
1,8302,1572,6753,3085,0625,2514,3754,8705,1555,576
86228591,7602714926944731,1801,176
Trade Payables430602473393527570596620725661
321373662576983836348359466588
Total Liabilities2,6273,7914,7066,0756,8837,1896,0526,3617,5658,040
7999181,0771,2681,7741,7712,3772,5362,5132,828
Capital Work in Progress3487411,1071,5701,9442,206601524837634
103299506833343219229227260271
5756708911,0731,3421,3971,2751,3531,9762,048
00000001,3401,4811,604
Cash & Bank71615137612228262129
7951,1489731,2941,4191,5741,541355477626
Total Assets2,6273,7914,7066,0756,8837,1896,0526,3617,5658,040

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
4454299667371,629674784773227809
Cash from Investing-511-794-754-822-836-369-461-329-636-483
Cash from Financing-9649880166-534-217-261-445404-318
-2809135-11619-408-2-68

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
69.6169.6169.6169.6769.6769.7469.7469.7469.87
4.323.944.173.943.964.054.234.264.17
15.4716.0516.0516.4316.4616.3016.1716.1715.93
Government0.000.000.000.000.000.000.000.000.00
10.6010.4010.169.969.909.929.869.8310.01

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-07
General Updates

2026-09-07 - Alembic Pharmaceuticals Limited has informed the Exchange about General Updates: : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Incorporation Of a Wholly Owned Subsidiary Company

2026-08-27
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-27
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-25
Copy of Newspaper Publication

2026-08-25 - Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-20
Change in Company Secretary/Compliance Officer

2026-08-20 - Alembic Pharmaceuticals Limited has informed the Exchange about Change in Company Secretary/Compliance Officer

2026-08-11
Copy of Newspaper Publication

2026-08-11 - Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-10
Resignation of Director/KMP/SMP

2026-08-10 - Alembic Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP

2026-08-10
Resignation

2026-08-10 - Alembic Pharmaceuticals Limited has informed the Exchange regarding Resignation of Ms. Manisha Saraf as Company Secretary & Compliance Officer of the company w.e.f. August 11, 2026.

2026-08-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-10 - Alembic Pharmaceuticals Limited has informed the Exchange about Transcript

News

Recent coverage and analyst commentary for APLLTD

Loading news…

🤖

AI Stock Analyst

Alembic Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login